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Abstract
Background: Mifepristone is approved to control hyperglycemia in adults with endogenous 
Cushing’s syndrome and is described as a mildly QTc prolonging drug, based on a TQT study. 
The aim of the present study was to assess the effect of mifepristone on the QTc interval at plas-
ma mifepristone concentrations exceeding those observed in the TQT study.
Methods: Twenty healthy, male volunteers were given three doses of 1200 mg mifepristone 
every 12 h with a high-fat meal in a randomized, placebo-controlled 2-period crossover study. 
Holter ECG recordings were made on Day 1 and 2.
Results: Eighteen subjects completed the study. Mean peak plasma mifepristone concentra-
tions were 4.01 µg/mL (CV: 31%) on the fi rst dose and 5.77 µg/mL (CV: 29%) on the third 
dose. Mifepristone did not have a meaningful QTc effect. The placebo-corrected, change-from-
-baseline QTcF (∆∆QTcF) was between –1.6 and 0.7 ms on the fi rst dose (upper bound of 90% 
CI 3.8 ms) and the largest ∆∆QTcF on the third dose was 4.9 ms (upper bound of 90% CI: 8.4 ms). 
Concentration effect modeling showed a slightly negative slope of –0.01 ms/ng/mL.
Conclusions: Mifepristone did not cause a clinically meaningful QTc prolongation in healthy 
volunteers at plasma concent rations of mifepristone and its main metabolites that clearly 
exceeded those seen in a previous TQT study. (Cardiol J 2013; 20, 2: 152–160)
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Introduction
Mifepristone (Korlym™) is an antagonist of the 
type II glucocorticoid receptor (GR-II) and progeste-
rone receptor approved with orphan-drug status as 
a once-daily oral medicine to control hyperglycemia 
in adult patients with endogenous Cushing’s syn-
drome who have failed surgery or who are not can-
didates for surgery [1]. Patients initiate mifepristone 
treatment at a dose of 300 mg/day administered with 
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food. The dose can then be titrated by 300 mg incre-
ments up to 1200 mg daily by assessing tolerability 
and degree of improvement [2].
Reported mifepristone pharmacokinetics are 
largely from studies using relatively low doses 
given as a single dose or for only a few days [3, 
4]. Over the whole dose range now studied, from 
2 to 1800 mg, mifepristone reveals complex phar-
macokinetics that at higher doses are not linear or 
dose proportional and are time-dependent. These 
features arise from its exclusive and extensive 
CYP3A metabolism, strong CYP3A inhibition 
leading to autoinhibited metabolism, and CYP3A 
autoinduction. Additionally, there may be some role 
for alpha acid glycoprotein binding at low doses 
and an absorption limit at high doses. There is also 
a dose dependent food effect that varies from none to 
greater than 50% increase in exposure for multiple 
doses from 300 mg and 1200 mg, respectively. The 
mean terminal half-life is long (2 to 4 days after 
multiple dosing). There are 3 major metabolites 
that have pharmacodynamic activities similar to, 
but less potent, than that of mifepristone. Desig-
ning a QT study for a drug with this constellation 
of properties is an interesting challenge.
Current labeling for mifepristone for Cushing’s 
syndrome warns against use with QT interval-
-prolonging drugs, or in patients with potassium 
channel variants resulting in a long QT interval 
[1]. This advice is based on the results of a parallel 
group thorough QT (TQT) assessment of therapeu-
tic (600 mg OD) and supratherapeutic (1800 OD) 
doses of mifepristone administered under fasting 
conditions for 14 days. The 1800 mg but not the 
600 mg dose caused a small mean QTc prolongation 
(placebo corrected change from baseline) of 3 to 
7 ms between 6 and 20 h post-dosing on Day 7 of 
dosing. No time-point had a 90% upper confi dence 
interval (CI) that exceeded 11 ms (data on fi le). 
In a concentration-response analysis, no PK/QTc 
relationship was identifi ed, but the dynamic range 
of plasma mifepristone concentrations was small 
at steady state. The study had a large number 
of subject dropouts, which complicated the data 
interpretation.
The rationale for the current study was to 
conduct a QT study in which higher plasma mife-
pristone concentrations than those observed in 
the TQT study were projected with shorter study 
duration in order to avoid CYP3A autoinduction. To 
achieve this, 1200 mg doses of mifepristone were 
given with food using a short course (every 12 h 
for 3 doses) placebo-controlled crossover study.
Methods 
Subjects
The study enrolled healthy non-smoking male 
volunteers without signifi cant medical history aged 
18–45 years with body mass indices (BMI) between 
19 and 32 kg/m2. Physical examinations, 12-lead 
ECGs, and clinical laboratory evaluations were 
performed within 30 days prior to dosing. Correc-
ted QT intervals (QTcF) ≤ 450 ms were required 
at screening. If appropriate, two approved forms 
of contraception were used by female partners 
of the male subjects for the duration of the study. 
Ingestion of citrus and quinine was avoided by 
subjects during the study. Except for paracetamol, 
over-the counter or prescription medications were 
not allowed within 30 days prior to fi rst study dose 
or during the study.
All volunteers gave written informed consent 
prior to any study related procedures. The study 
was approved by an independent Ethics Commit-
tee (Plymouth Independent Ethics Committee) 
and conducted in accordance with the Declaration 
of Helsinki and Good Clinical Practice guidelines 
as set forth by the International Conference on 
Harmonisation and the U.S. Code of Federal Re-
gulations.
Study design 
The study was randomized, double blind and 
placebo-controlled, and used a 2-way crossover 
design performed at a single clinical site. Subjects 
were randomized as they completed screening 
assessments 1:1 to 1 of 2 treatment sequences. 
There was a 2-week washout period between 
periods.
In each period, subjects received either oral 
mifepristone 1200 mg or matching placebo in 
a double-blinded fashion every 12 h for 3 doses, 
on the morning and evening of Day 1 and morning 
of Day 2. Each treatment was administered within 
30 ± 15 min of a high fat (50% fat) meal with room 
temperature water. Participants were confi ned to 
the clinical centre on Days 1–3 of each dosing pe-
riod and returned for the end-of-study visit.
ECG recordings
Electrocardiograms (ECG) were obtained 
digitally using a continuous 12-lead Holter recorder 
(Global Instrumentation® M12R, Buffalo, NY). The 
recording started 1 h before dosing on Day 1 and 
continued until 24 h after dosing on Day 2. Record-
ings were stored on electronic media and were 
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shipped to the central ECG laboratory (iCardiac 
Technologies, Rochester, NY) after each dosing 
cohort. ECGs were extracted from the continuous 
recordings at the same time points as blood draws 
(see below). Subjects rested in the semi-recumbent 
or supine position for at least 10 min before and 
5 min after each of these time points. Using the 
TQTPlus® Technique (iCardiac Technologies, 
Rochester, NY), 10-s digital 12-lead ECG tracings 
were extracted from the continuous recordings us-
ing criteria for signal-to-noise ratio and stability of 
heart rate (HR). Ten replicate ECGs were extrac-
ted in close succession within each extraction win-
dow. QT interval measurements were performed 
using the High Precision QT Analysis (HPQT) 
technique, which utilises the COMPAS® software 
for interval measurements. All recorded cardiac 
beats in all replicates were assessed for quality, and 
signal-to-noise ratios were categorized as of “high” 
or “low” confi dence. All “high confi dence” beats 
were accepted into the analysis without manual 
adjustment, whereas all “low confi dence” beats 
were fully reviewed manually and adjudicated using 
pass-fail criteria [5]. Final quality assessment was 
performed by a board certifi ed cardiologist. Review 
of ECGs from a particular subject was performed 
by a single reader and baseline and on-treatment 
ECGs measurements in a subject were based 
on the same lead. For PR and QRS intervals and 
T-wave morphology, 3 of the 10 ECG replicates 
with the highest signal to noise ratio were selected 
for review. The median QT and RR value from each 
of the 10 extracted replicates was calculated and 
the mean of all available medians from a nominal 
time point was used as the subject’s reportable 
value at that time point.
Pharmacokinetic sampling
Serial 12-h mifepristone and active metabo-
lite plasma concentration profi les were collected 
within 30 min prior to dosing and at 0.5, 1, 1.5, 2, 
3, 4, 5, 6, 7, 8, 10, and 12 h after Dose 1 (Day 1) 
and Dose 3 (Day 2) of both periods. An additional 
blood sample was taken on Day 3, 24 h after the 
last dose of medication. Total plasma concentra-
tions of mifepristone and the 3 active metabolites 
RU 42633 (mono-demethylatedmetabolite), RU 
42698 (hydroxylated metabolite) and RU 42848 
(di-demethylatedmetabolite) were determined 
by MicroConstants (San Diego, California) using 
a validated liquid chromatography assay method 
with tandem mass spectrometry (LC/MS/MS). 
The limits of quantitation were 10 ng/mL for each 
analyte. 
Safety determinations
Safety assessments included measurement of 
vital signs (blood pressure, HR, respiratory rate, 
and oral temperature), 12-lead ECGs, clinical labo-
ratory tests, and adverse event monitoring. 
Analyses and statistics
Based on the TQT study where an 1800 mg 
mifepristone dose caused a small mean QTc prolon-
gation (placebo corrected change from baseline) of 
3 to 7 ms between 6 and 20 h post dosing on Day 7
of dosing, the study was calculated to have 80% 
power to exclude an effect of 15 ms at all time po-
ints on Day 2 with 16 subjects assuming standard 
deviation of the change from baseline QTc of 7 ms 
and independence between the tests at different 
time points. Data from all randomised subjects 
were included in the ECG analyses. Safety analyses 
included all subjects receiving study treatments. 
Pharmacokinetic analyses were performed on all 
subjects treated with mifepristone from whom 
at least one post dose sample above the limit of 
quantitation was obtained. Statistical reporting was 
performed using R for Windows (v2.13.0).
ECG analyses. Descriptive statistics (e.g., 
frequency, percent, mean, standard deviation [SD], 
coeffi cient of variation [CV%], median, maximum 
and minimum) were used to summarize the QTc, 
and other ECG variables (HR, PR, RR, and QRS 
intervals), and corresponding changes from ba-
seline. The primary endpoint was QTcF (= QT/
/RR0.33) [6]. For each time point, a linear mixed 
effects model was fi tted with QTcF as dependent 
variable, sequence, period, and treatment as fi xed 
effects, baseline as covariate and subject (inter-
cept) as random effect. A 2-sided 90% CI was cal-
culated for the contrasts “mifepristone – placebo” 
DQTcF(DDQTcF). 
Analysis of QTc outliers (QTcF > 450 ms, 
> 480 ms and > 500 ms and DQTcF > 30 ms and 
> 60 ms) and treatment emergent changes of 
T-wave morphology was performed.
Pharmacokinetic analyses. Maximum peak 
concentration (Cmax), time to maximum concen-
tration (Tmax), and the area under the concentra-
tion-time curve from 0 h to 12 h (AUC0–12 computed 
using the linear trapezoidal rule) were derived from 
the plasma concentration profi les for mifepristone 
and its metabolites after dose 1 and dose 3. Stan-
dard non-compartmental computation methods 
were used (WinNonlin® Professional version 5.2, 
Pharsight, St. Louis, MO). Summary statistics 
included count, mean, median, SD, minimum, 
maximum, CV% and a 2-sided 90% CI.
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Pharmacokinetic/pharmacodynamic ana-
lyses. The relationship between plasma concentra-
tion of mifepristone and metabolites and DDQTcF 
was investigated using a linear mixed-effect model:
DDQTcFij = Intercepti + Slopei × Concij + eij
where DDQTcFij was the time-matched, placebo-
-corrected change-from-baseline QTcF for subject 
i at time j with mifepristone or its main metabolites 
concentration Concij. Time matched concentra-
tion was included in the model as a variable and 
subjects as a random effect for both intercept and 
slope, whenever applicable. The residual eij was 
assumed to be identical, independent, normally 
distributed with mean 0 and variance s2. Three 
models were used where Model 1 used a fi xed and 
random intercept, Model 2 set the fi xed intercept 
to 0 but allowed for a random intercept and Model 
3 had no intercept.
A plot of standardized residuals vs. fi tted va-
lues was used to examine departure from model 
assumptions. In addition, normal Q-Q plots of the 
random effects and the within-subject errors were 
used to investigate the normality of the random 
effects and the within-subject errors, respectively. 
A fi nal assessment of the adequacy of the linear mixed 
effects model was provided by a goodness-of-fi t plot 
(i.e. the observed concentration quantile-DDQTcF 
plot) [7] to check both the assumption of linearity 
between the concentrations of mifepristone or its 
main metabolites and DDQTcF and how well the 
predicted DDQTcF matched the observed data in 
the regions of interest. The goodness-of-fi t plot 
was generated by binning the independent variable 
of concentration into deciles. The mean DDQTcF 
with 90% CI within each decile was computed and 
plotted at the corresponding median concentration 
within the decile [7]. The model providing the 
best fi t as judged from the diagnostic plots and the 
Akaike Information Criterion was to be selected. 
Results
Twenty male subjects were randomized  and 
18 completed the study. Two subjects were disconti-
nued, one due to and adverse event of skin rash and 
one due to elevated ALT. A third subject withdrew 
consent during the fi rst dosing period, but reentered 
the study for the second dosing period. The majority of 
subjects were Caucasian (13/20, 65%), 3 were Black/
/African American (15%), 2 were Asian (10%) and 
2 were categorized as Other race (10%). Mean ± SD 
age was 31 ± 4 years and BMI was 25 ± 3 kg/m2.
QTc analyses
On both Day 1 and Day 2, the DQTcF diurnal 
pattern was similar during the placebo and the 
mifepristone treatments, with a shortening during 
the fi rst 10 h post-dosing (Fig. 1). On Day 2, the 
DQTcF shortening was somewhat larger on mi-
fepristone than on placebo. Later during Day 2, 
DQTcF was similar on both treatments, with the 
exception of the 24-h time point. At this time point, 
which occurred in the morning on Day 3, DQTcF 
was –2.3 ms for placebo and 2.6 ms for mifepristone. 
The resulting mean placebo-corrected DQTcF 
(DDQTcF) was within a very narrow range on Day 1,
–1.6 to 0.7 ms (Fig. 2), and the upper bound of 
the 90% CI was below 4 ms at all time points 
(Table 1). On Day 2, there was an initial shortening 
of the QTc interval with mean DDQTcF between 
–1.7 and –5.2 ms. Mean DDQTcF thereafter remained 
around 0 ms (–1.5 to 0.8 ms) between 5 and 12 h after 
dosing, whereas the 24-h value (i.e., in the morning 
of Day 3) reached 4.9 ms (90% CI 1.4–8.4 ms). The 
upper bound of the 90% CI was well below 10 ms 
at all time points (Table 1).
There were no subjects with absolute QTcF 
values exceeding 480 ms or DQTcF exceeding 
30 ms. All subjects had QTcF values less than 450 ms
at all time points except 1 subject with a QTcF 
value that exceeded 450 ms at the 24-h time point 
of Day 2. The only observed T-wave abnormality 
was fl attened T-waves, which was seen at 1 time 
point on placebo and 1 time point on mifepristone.
The mean SD of DQTc across time points was 
below 7.0 ms for mifepristone on Day 1 and placebo 
on both days, whereas the precision was somewhat 
lower for mifepristone on Day 2 (mean of 7.8 ms).
Heart rate, PR and QRS, 
ECG morphology a nalysis
On both Day 1 and Day 2, change-from-baseli-
ne heart rate (DHR) was small at all time points for 
both placebo and mifepristone. On Day 1, placebo-
-corrected DHR (DDHR) showed a slight lowering 
of the mean HR of up to 3.7 bpm during the fi rst 
2 h after dosing, after which the HR was unchanged 
throughout the dosing interval. On Day 2, the same 
pattern was observed with a slight lowering of 
2 to 3 bpm immediately after the morning dose with 
somewhat higher values in the afternoon.
A small PR interval shortening was observed 
on both placebo and on mifepristone on Day 1 and 
on Day 2, with change-from-baseline PR (DPR) re-
aching –5 to –6 ms (data not shown). The placebo-
-corrected DPR (DDPR) varied between –3.0 ms 
and 4.7 ms on Day 1 and -3.7 ms and 2.1 ms on 
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Day 2. Mifepristone did not have an effect on QRS 
duration and DDQRS was essentially unchanged 
with all values within ± 1.0 ms.
Pharmacokinetic parameters
Cmax and AUC0–12 increased from dose 1 to 
dose 3 for both mifepristone and its metabolites 
(Table 2); the mean ratio for Cmax between dose 
3 and dose 1 was 1.50 for mifepristone, 1.04 for RU 
42633, 1.29 for RU 42698 and 1.39 for RU 42848. 
For AUC0–12 the accumulation between dose 1 and 
dose 3 was generally higher than for Cmax with 
ratios of 1.62, 1.10, 1.44 and 1.65 for mifepristone, 
RU 42633, RU 42698 and RU 42848, respectively. 
Overall, the accumulation observed for mifepri-
stone, RU 42698 and RU 42848 was modest, and 
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1200 mg mifepristone
Placebo
D
Q
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F
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Figure 1. Change-from-baseline QTcF (DQTcF, mean ± SE) on Day 1 (A) and Day 2 (B).
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Figure 2. Placebo-corrected change-from-baseline QTcF (∆∆QTcF, mean with 90% confidence intervals) on Day 1 
and Day 2.
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Table 1. Plac ebo-corrected changes from Day 1 redoes baseline QTcF (DDQTcF, ms) across time points.
Time point [h] Day 1 Day 2
[ms] mean ± SE 90% CI [ms] mean ± SE 90% CI
0 NA NA –4.0 ± 1.3 –6.1 to –1.9
0.5 –0.5 ± 2.0 –3.8 to 2.7 –5.0 ± 2.4 –8.9 to –1.1
1 –1.2 ± 1.6 –3.8 to 1.4 –5.2 ± 2.1 –8.7 to –1.7
1.5 –1.5 ± 1.6 –4.2 to 1.2 –4.8 ± 1.9 –7.9 to 1.7
2 –0.7 ± 0.9 –2.2 to 0.7 –5.0 ± 2.1 –8.6 to –1.5
3 0.2 ± 1.2 –1.8 to 2.2 –2.3 ± 2.0 –5.5 to 0.9
4 –0.8 ± 1.4 –3.2 to 1.5 –1.7 ± 1.9 –4.9 to 1.5
5 0.7 ± 1.9 –2.4 to 3.8 0.8 ± 2.1 –2.7 to 4.3
6 –0.8 ± 1.5 –3.4 to 1.7 –1.5 ± 1.5 –4.0 to 1.0
7 –1.6 ± 1.4 –3.9 to 0.8 0.7 ± 1.7 –2.1 to 3.5
8 –1.3 ± 2.0 –4.5 to 1.9 –0.1 ± 1.7 –2.9 to 2.8
10 –0.1 ± 1.1 –1.9 to 1.8 –1.0 ± 1.7 –3.8 to 1.8
12 –1.5 ± 1.5 –4.0 to 0.9 0.6 ± 2.5 –3.5 to 4.8
24 4.9 ± 2.1 1.4 to 8.4
Table 2. Pharmacokinetic parameters (mean; CV%) of mifepristone and metabolites.
Analyte Day Tmax [h] Cmax [µg/mL] Ctrough [µg/mL] AUCt [h × µg/mL]
Mifepristone 1 N 20 20 19 20
Mean 4.37 4.01 2.05 30.9
CV% 43.8 30.6 35.0 30.5
2 N 18 18 18 18
Mean 5.13 5.77 3.70 49.0
CV% 55.1 28.8 41.5 28.6
RU 42633 1 N 20 20 19 20
Mean 6.70 3.02 2.60 27.2
CV% 37.7 41.7 32.5 31.2
2 N 18 18 18 18
Mean 8.21 2.93 2.57 28.9
CV% 47.8 31.1 34.9 29.2
RU 42698 1 N 20 20 19 19
Mean 10.36 0.78 0.74 6.45
CV% 25.3 34.4 39.8 33.2
2 N 18 18 18 18
Mean 7.24 0.97 0.88 9.26
CV% 69.1 34.5 38.3 31.3
RU 42848 1 N 20 20 19 20
Mean 10.41 1.51 1.44 12.1
CV% 20.3 35.3 29.4 28.9
2 N 18 18 18 18
Mean 8.99 1.96 1.82 19.2
CV% 37.1 33.3 36.2 26.8
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RU 42633 had little, if any, accumulation. Tmax for 
mifepristone changed little between dose 1 (4.4 h; 
CV 44%) and dose 2 (5.1 h; CV 55%).
Pharmacokinetic/pharmacodynamic 
relationships
Model 2 with mean intercept fi xed to 0 (with 
variability) was found to fi t the data best, i.e., provided 
the best fi t as judged from the diagnostic plots and the 
Akaike Information Criterion among the 3 candidate 
models and was therefore chosen for the analysis.  
Given the long half-life of mifepristone and 
its metabolites, analysis of the predose sample 
on Day 1 in period 2 from 9 subjects who were 
treated with the sequence mifepristone ® placebo 
was performed. In 7/9 of these subjects, low but 
quantifi able levels of mifepristone (mean 0.51 ± 
± 0.34 µg/mL) and of its metabolites were detected. 
Therefore, data from only the 10 subjects who 
received placebo in period 1 and mifepristone in 
period 2 was used in the primary PK-QTc analysis. 
For the secondary PK-QTc analysis, data from all 
20 subjects were used.
Concentration effect modeling demonstrated 
a slightly inverse relation between mifepristone 
plasma concentrations and DDQTcF with a negative 
slope of –0.0010 ms/ng/mL (CI: –0.0014 to –0.0005; 
p = 0.0004) in the primary analysis (that included 
only subjects dosed in sequence placebo – mifepri-
stone) and a non-signifi cant slope of –0.0010 ms/
/ng/mL (CI: –0.0026 to 0.0005; p = 0.2731) in the 
secondary analysis, which included all 20 subjects. 
The goodness-of-fi t plot (Fig. 3) shows the mean 
DDQTcF (90% CI) within each mifepristone plasma 
concentration decile and the model-predicted mean 
DDQTcF with 90% CI. The predicted DDQTcF at 
the observed mean peak plasma concentration of 
5.77 µg/mL was –5.7 ms, which is consistent with 
the results of the time-matched analysis. 
None of the 3 major metabolites of mifepristo-
ne were associated with a concentration dependent 
prolongation of DDQTcF (data not shown).
Tolerability
Fifteen (75%) subjects experienced 44 tre-
atment emergent adverse events during the mi-
fepristone periods and 6/20 (30%) experienced 
11 events during the placebo periods. The majority 
of adverse events were mild in intensity (39/44, 
89% in the mifepristone periods and 9/11, 81% 
in the placebo periods). The remainder of events 
was of moderate intensity. There were no serious 
adverse events. Common events (occurring in 
³ 3 subjects) during the mifepristone periods were 
abdominal cramps, dry mouth, headache, insomnia, 
dizziness, and rash. 
There were no clinically signifi cant changes in 
clinical laboratory measurements, vital signs, ECG 
safety parameters, or physical fi ndings other than 
the 1 subject withdrawn due to elevated ALT. The 
subject had an elevated ALT of 159.5 IU/L conside-
red clinically signifi cant. Upon retesting 24 h later, 
ALT level remained elevated and the subject was 
withdrawn. ALT level was within normal range 
upon retesting 1 week later.
Discussion
Mifepris tone was recently approved in the 
US with the indication to control hyperglycemia 
in adult patients with endogenous Cushing’s syn-
drome who have failed surgery or who are not 
candidates for surgery [8]. The label states that 
mifepristone prolongs the QT interval in a dose-
related manner and includes cautionary statements 
that are based on the results of a previous multiple 
dose TQT study conducted over 14 days.
The current study was designed to assess the 
ECG effects of mifepristone at plasma drug con-
Figure 3. Observed and predicted relation between mi-
fepristone plasma levels and DDQTcF. Primary analysis 
in 10 subjects from dosing sequence Placebo ® Mife-
pristone. Blue vertical bars show the observed mean 
DDQTcF with 90% confidence interval (CI) within each 
plasma concentration decile. The solid black line with 
gray shaded area represents the model-predicted mean 
DDQTcF with 90% CI. The horizontal blue lines with not-
ches show the range of plasma concentrations within 
each decile.
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centrations that clearly would exceed those seen 
in patients on chronic dosing with the maximum 
recommended dose 1200 mg once daily. Mifepristo-
ne has complex metabolism that leads to pharma-
cokinetics that are not linear or dose-proportional, 
and are time dependent. Even though the mean 
terminal half-life of the drug after multiple dosing 
is long (2 to 4 days in healthy subjects), drug ex-
posure at steady state is similar to that of the fi rst 
dose. To overcome the increased clearance of the 
drug with multiple dosing and obtain suprathera-
peutic plasma drug concentrations, a short-term 
dosing schedule was used with 3 doses of 1200 mg 
administered every 12 h with serial ECG assess-
ment on 2 consecutive days. Since food increases 
mifepristone exposure, the drug was administered 
with a high-fat meal. Mean mifepristone Cmax rea-
ched 4.01 µg/mL after the fi rst dose on Day 1 and 
5.77 µg/mL after the third dose on Day 2, compared 
to that of 3.92 ± 1.37 µg/mL (95% CI 3.56–4.28) at 
steady-state for fasted subjects given an 1800 mg
dose. Therefore, the dosing strategy of a short 
course with food provided exposures comparable to 
and higher than those of the TQT study at steady 
state with the fi rst and third doses respectively.
To increase the power of the study to exclude 
small QTc effects, a 2-way crossover design was 
chosen with placebo and mifepristone in separate 
treatment periods. The study did not fulfi ll standard 
criteria for a TQT study as it did not include a po-
sitive control, but otherwise incorporated all TQT 
design-elements including strict control of experi-
mental conditions and serial ECG recordings to 
capture effects observed at Cmax of both parent and 
major metabolites [9]. A high-precision QT meas-
urement technique was used to increase the power 
of the assessment further. The achieved precision, 
measured as the SD of ∆QTcF, confirmed this 
approach: the mean SD of ∆QTcF of 7.0 to 7.8 ms 
for both mifepristone and placebo compares fa-
vorably with other ‘manually overseen’ highly 
precise technologies, such as Eclysis [10], and 
is better than the precision typically achieved 
with standard semi-automated methods [5]. The 
results of the QT assessment were solidly ne-
gative in terms of the study’s ability to exclude 
a QTcF effect exceeding 10 ms with the E14-defi ned 
time-matched analysis [11, 12]. The  results of 
the concentration-effect analysis were consistent 
with the time-matched analysis and demonstrated 
a reverse relation between mifepristone plasma 
concentrations and ∆∆QTcF with a negative slo-
pe of –0.0010 ms/ng/mL (CI: –0.0014 to –0.0005; 
p = 0.0004). With a relatively small sample size of 
20 subjects, it was thereby possible to exclude that 
plasma mifepristone concentrations exceeding those 
seen in the previous TQT have an effect on cardiac 
repolarization that would be of clinical concern. 
These fi ndings are in contrast to the results 
of an earlier parallel group TQT study in healthy 
subjects, conducted with 2 doses of mifepristone 
(a therapeutic 600 mg dose and a supratherapeutic 
1800 mg dose) and placebo. On Day 7, mifepristone 
1800 mg OD caused a small QTc prolongation of 
3 to 7 ms (∆∆QTcI); the upper bound of the 90% 
CI did not exceed 11 ms at any time point. On the 
same day, the mean ∆∆QTcI in the mifepristone 
600 mg group was below 5 ms with all upper 
bounds of the CI below 10 ms. Concentration-effect 
analysis showed no correlation of the observed QTc 
prolongation to either parent or any of the metabo-
lites alone. Based on the TQT study, mifepristone 
seemed to cause a mild QTc prolongation with 
chronic dosing, with an apparent dose-response 
but unrelated to drug exposure. QTc effect with 
chronic dosing may therefore have a different 
underlying mechanism than direct inhibition of 
the hERG channel by the drug or its metabolites. 
Two potential mechanisms could be hypothesized, 
even though fi rm data supporting either one are 
lacking: an effect on hERG protein traffi cking and/
/or an indirect pharmacodynamic effect.
Some drugs inhibit the transport of hERG 
proteins, or components thereof, from the en-
doplasmic reticulum to the cell membrane; this 
results in a reduction of the number of functional 
hERG channels at the cell surface, which may 
lead to QT prolongation. QT prolongation via this 
mechanism is not typically seen acutely but after 
some days of treatment. Examples of drugs that 
cause QT prolongation thorough inhibition of hERG 
traffi cking are arsenic trioxide, pentamidine, and 
fl uoxetine [13–18].The second and perhaps more 
likely mechanism is that mifepristone causes QT 
prolongation through an indirect mechanism. Mife-
pristone blocks the cortisol receptor and this leads 
to high circulating cortisol concentrations through 
feedback on the hypothalamic-pituitary axis. Eleva-
ted cortisol levels may activate mineralocorticoid 
receptors and this can lead to cellular potassium 
loss, which as such can result in prolongation of the 
QT interval. Small perturbation of the potassium 
balance in the myocardial cells may not be appa-
rent from sampling in peripheral blood and may 
have contributed to the mild QT effect observed 
on chronic dosing. 
The discrepancy between the present short-
-term study and the earlier TQT study with chronic 
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dosing cannot be defi nitively explained without 
further studies. QT prolongation may be multifac-
torial and not always directly related to plasma con-
centrations of a drug or its metabolites. Further-
more, using single doses of drug to determine QTc 
effect may still in some cases leave uncertainty 
about the QTc effect of chronic dosing. Nonethe-
less, by combining concentration-effect modeling, 
an effi cient design and a high precision QT mea-
surement technique, a QTc effect exceeding 10 ms 
could be confi dently excluded despite a relatively 
small sample size, which was substantially smaller 
than in most TQT studies [9]. Mifepristone has 
complex metabolism and it is diffi cult to achieve 
supratherapeutic exposure with chronic dosing. 
This study therefore also illustrates how a tailored 
approach based on known PK profi le of a drug can 
results in high plasma levels despite somewhat 
unusual circumstances: in this case, a short-term 
frequent dosing schedule with high doses of the 
drug administered twice as often as intended in 
clinical practice and with a high-fat meal.
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